ARTICLE | Company News
Pfenex, Hospira deal
February 16, 2015 8:00 AM UTC
Pfenex granted Hospira exclusive, worldwide rights to develop and commercialize PF582, a biosimilar of ophthalmic drug Lucentis ranibizumab. Pfenex will receive $51 million up front and is eligible ...